Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

To evaluate the safety and efficacy of beta-blockers (BBs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists (ARBs), mineralocorticoid receptor antagonists (MRAs), and angiotensin receptor neprilysin inhibitors (ARNIs) for the treatment of patients with heart failure (HF) with preserved ejection fraction (HFpEF).

This is a protocol.

Share/Save
Health topics: